ASSOCIATION OF SERUM CA-125 LEVELS WITH NON-HODGKIN’S LYMPHOMA
DOI:
https://doi.org/10.69656/pjp.v13i1.269Keywords:
Non-Hodgkin’s Lymphoma, Serum CA-125, International Prognostic Index (IPI)Abstract
Background: Non-Hodgkin’s lymphoma (NHL) is a common malignancy presenting to oncology out-patient departments. Several prognostic markers including lactate dehydrogenase (LDH), BCL-2 and beta-2 micro-globulin have been studied and have been found to be of significance. Serum CA-125 has been studied in the past and feeble but unclear association was found. The present study aims at finding an association between serum CA-125 levels and NHL. Methods: One hundred patients (90 males, 10 females) with histological diagnosis of NHL diffuse large B-cell type were enrolled in the study through convenience sampling method. After documenting the demographics (age, gender and performance status), staging investigations including bone marrow aspiration/trephine, CT scans, baseline haematology and biochemistry. Serum LDH and serum CA-125 levels were measured at diagnosis and completion of treatment. Results: Fifty-eight patients had normal serum CA-125 levels while 42 patients had raised levels. Patients with high CA-125 levels at baseline had higher international prognostic scores. These patients had poorer response to treatment. Raised CA-125 levels were found more frequently among patients who had ascites or pleural effusions due to lymphoma. Conclusion: Serum CA-125 level measurement before during and after treatment correlates with response to treatment and increasing levels following treatment completion can predict disease relapse ahead of time.
Pak J Physiol 2017;13(1):54–6
Downloads
References
2. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, et al. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. JAMA Oncol 2016;2(11):1427.
3. Semedo BYD. Cancer Antigen 125 as diagnostic test for endometrio sis questioned. Endometriosis News 2016. p. 1–3.
4. Bast Jr. RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68(5):1331–7.
5. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015;33(18):2062–71.
6. Oriordan DK, Deery A, Dorman A, Epstein OE. Increased Ca-125 in a patient with tuberculous peritonitis –Case-report and Review of published works. Gut 1995;36:303–5.
7. Sandoval JA, Malkas LH, Hickey RJ. Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors. Int J Mol Sci 2012;13(1):1126–53.
8. Kontoninas Z, Kaiafa GD, Saouli Z, Savopoulos CG, Triantafyllos D. Tumor markers in diagnosis and follow up of haematologic malignancies. Blood 2016;128(22):5337.
9. Afshan A, Sadaf N. Primary ovarian lymphoma –a rare entity. J Pak Med Assoc 2013;63(4):519–20.
10. Jia-Zhu W, Tian T, Ying H, Jin Hua L, Yi M, Li W, et al. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma. Cancer Biomarkers 2016;17(2):205–12.
11. Lokanathan V, Gupta G, Ghalaut VS, Ghalaut PS, Mahor DS, Mahor A. CA125 in Non Hodgkin’s Lymphoma and its association with severity of the disease. Am Multidiscip Int Res J 2015;2(4):1–6.
12. Ziddan J, Hussein O, Basher W, Zohar S. Serum CA125: A tumor marker for monitoring response to treatment and follow-up in Patients with Non-Hodgkin’s Lymphoma. Oncologist 2004;9(4):417–21.
13. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive Non-Hogkin’s Lymphoma. N Engl J Med 1993;328(23):1676–85.
14. Memar B, Aledavood A, Shahidsales S, Ahadi M, Farzadnia M, Raziee HR, et al. The prognostic role of tumor marker CA-125 in B-cell non-Hodgkin’s Lymphoma. Iran J Cancer Prev 2015;8(1):42–6.
15. Procházka V, Faber E, Raida L, Kapitáňová Z, Langová K, Indrák K, PapajÃk T. High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score. Int J Hematol 2012;96(1):58–64.
16. Burney IA, Siddiqui T, Siddiqui I. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin’s lymphoma. Cancer 1999;85(3):755–6.
17. Batlle M, Ribera JM, Oriol A, Pastor C, Mate JL, Fernández-Avilés F, et al. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin’s lymphoma: study of 200 patients. Leuk Lymphoma 2005;46(10):1471–6.
18. El Gawad I, Shafik H. CA 125, a new prognostic marker for aggressive NHL. J Egypt Natl Canc Inst 2009;21(3):209–17.
19. Zacharos I, Efstathiou S, Tsioulos D, Mastorantonakis S, Roussou P. The prognostic significance of CA 125 in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002;69(4):221–6.
20. Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I, et al. Serum CA 125 as a prognostic factor in non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(10):1733–8.
21. Hazarika N, Dhabhar B, Saikia TK. Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass –a diagnostic dilemma. J Assoc Physicians India 2008;56:47–8.
Downloads
Published
How to Cite
Issue
Section
License
Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.
